{"url_path":"/sec/sgmo/10-k/2026/item-2","section_key":"item-2","section_title":"Item 2 PROPERTIES","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-03-30","source_url":"https://www.sec.gov/Archives/edgar/data/1001233/0001628280-26-022029-index.html","accession_number":"0001628280-26-022029","cik":"0001001233","ticker":"SGMO","issuer_name":"SANGAMO THERAPEUTICS, INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1001233/0001628280-26-022029-index.html","primary_entity_key":"0001001233","primary_entity_name":"SANGAMO THERAPEUTICS, INC"},"word_count":93,"has_tables":true,"body_markdown":"ITEM 2 – PROPERTIES\n\nOur corporate headquarters occupies approximately 59,485 square feet of research and office space, pursuant to a lease that expires in August 2031, and we occupy approximately 7,700 square feet of office space, pursuant to a lease that expires in August 2026, in Richmond, California. We also lease approximately 103,089 square feet of office space and a research and\n\n95\n\n[Table of Contents](#i29aeb4416f69482f8f7bc32e0d48731a_7)\n\ndevelopment laboratory facility in Brisbane, California, pursuant to a lease that expires in May 2029. We believe that our facilities are currently adequate to meet our needs."}